The merger forms a new parent organization, Healthcare Revolution Partners, designed to tackle the growing demand for transparency and cost-efficiency in prescription care. By integrating Abarca’s Darwin Healthcare Intelligence platform with LucyRx’s clinical infrastructure and Connected Specialty Care Network, the companies aim to streamline administrative operations and lower total costs for commercial and government clients alike.

Despite the consolidation, both brands will retain their current identities and leadership teams. Jason Borschow will remain CEO of Abarca, while David Blair continues to lead LucyRx; both will serve as co-chairs of the parent company. Operations will remain distinct, with Abarca focusing on government programs and health plans, and LucyRx concentrating on employers and third-party administrators. The transition is expected to close in the third quarter of 2026, pending regulatory approval, with no planned disruptions to existing client services or account management.